Skip to content

Study · Animal study (in vivo) · mouse · 1982

4 results

Activation of polyclonal antibody responses by a synthetic serum thymic factor (FTS) in CBA/N mice.

Matsumoto T, Shibata M

Immunology1 Feb 1982Cited by 3 (Europe PMC)

PMID7037618 (opens in a new tab)PepBankPUB-07037618
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In CBA/N mice and affected F1 hybrids, in vivo FTS treatment augmented subsequent in vitro LPS-induced polyclonal B-cell responses.

    In plain wordsIn CBA/N mice and affected hybrids, FTS treatment increased the subsequent laboratory B-cell response to LPS.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreaseLPS-induced polyclonal B-cell responses
    Study

    mousen: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · injectionAs given in this study (mouse).

    Source sentences

    Summary
    A synthetic serum thymic factor (FTS) augmented the lipopolysaccharide (LPS)-induced polyclonal B-cell responses in vitro of CBA/N mice and their F1 hybrids having an X-linked B-cell defect.
    1 context sentence
    Summary · context
    For this augmentation, FTS should be injected in vivo.
  2. 02AnimalAnimal study (in vivo)Activity measurement

    Splenic B cells from FTS-treated mice with the CBA/N defect accepted help from normal or immunodeficient T cells.

    In plain wordsIn mice with the CBA/N defect, B cells accepted T-cell help after FTS treatment.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreaseB-cell receptivity to T-cell help
    Study

    mousen: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · injectionAs given in this study (mouse).

    Source sentences

    Summary
    Splenic B cells derived from FTS-treated mice with the CBA/N defect were receptive to T-cell help from normal or immunodeficient mouse T cells.
  3. 03AnimalAnimal study (in vivo)Activity measurement

    In ATXBM CBA/N mice, FTS treatment after cell transfer did not increase the B-cell response.

    In plain wordsIn ATXBM CBA/N mice, FTS treatment after cell transfer did not increase the B-cell response.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeB-cell response in ATXBM mice
    Study

    mousen: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · injectionAs given in this study (mouse).

    Source sentences

    Summary
    Spleen cells from ATXBM CBA/N mice treated with FTS 3 weeks after cell transfer did not increase the B-cell response.
  4. 04AnimalAnimal study (in vivo)Activity measurement

    B cells from FTS-treated male F1 mice retained neonatal characteristics, shown by inhibition with antimouse Ig and anti-Ia sera.

    In plain wordsIn male F1 mice, B cells retained neonatal characteristics after FTS treatment.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    Not applicableNeonatal B-cell characteristics
    Study

    mousen: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · injectionAs given in this study (mouse).

    Source sentences

    Summary
    B cells from FTS-treated male F1 mice with the CBA/N defect still have characteristics of neonatal mouse B cells as revealed by inhibition with antimouse Ig and anti-Ia sera.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.